DEVELOPMENT OF A NOVEL VASCULAR DISRUPTING AGENT FOR ADVANCED PROSTATE CANCER

$999,699FY2011Department of the ArmyDOD

Synta Pharmaceuticals Corp.

Investigators

View source on USAspending →